| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Protooncogene Gankyrin is overexpressed in ovarian cancer. Gankyrin accelerates to degrade pRb protein. Gankyrin inhibits the interaction of p16INK4a with cdk4. Gankyrin enhances to degrade p53 protein by MDM2. Gankyrin suppresses the activity of NFkappaB, partly due to recruitment of SIRT1 histone deacetylase to NFkappaB protein. HSCO gene is overexpressed in ovarian cancer. HSCO inhibits the activity of p53 due to recruitment of HDAC1 histone deacetylase to p53 protein. Gankyrin and HSCO activate the activity of HDACs. These enhanced activities of HDACs accelerate to grow cancer cells more aggressively. The activities of invasion and metastasis are enhanced due to these activated HDACs. Nicotinamide suppresses SIRT1 activity. TSA(Trichostatin A) inhibits HDAC1 activity. These HDAC inhibitors suppress the growth, invasion, and metastasis of cancer cells.
|
